作者
Seung-Jung Park, Duk-Woo Park, Young-Hak Kim, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Ki-Hoon Han, Seong-Wook Park, Sung-Cheol Yun, Sang-Gon Lee, Seung-Woon Rha, In-Whan Seong, Myung-Ho Jeong, Seung-Ho Hur, Nae-Hee Lee, Junghan Yoon, Joo-Young Yang, Bong-Ki Lee, Young-Jin Choi, Wook-Sung Chung, Do-Sun Lim, Sang-Sig Cheong, Kee-Sik Kim, Jei Keon Chae, Deuk-Young Nah, Doo-Soo Jeon, Ki Bae Seung, Jae-Sik Jang, Hun Sik Park, Keun Lee
发表日期
2010/4/15
期刊
New England Journal of Medicine
卷号
362
期号
15
页码范围
1374-1382
出版商
Massachusetts Medical Society
简介
Background
The potential benefits and risks of the use of dual antiplatelet therapy beyond a 12-month period in patients receiving drug-eluting stents have not been clearly established.
Methods
In two trials, we randomly assigned a total of 2701 patients who had received drug-eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months to receive clopidogrel plus aspirin or aspirin alone. The primary end point was a composite of myocardial infarction or death from cardiac causes. Data from the two trials were merged for analysis.
Results
The median duration of follow-up was 19.2 months. The cumulative risk of the primary outcome at 2 years was 1.8% with dual antiplatelet therapy, as compared with 1.2% with aspirin monotherapy (hazard ratio, 1.65; 95% confidence interval [CI], 0.80 to 3.36; P=0.17). The individual risks of myocardial …
引用总数
学术搜索中的文章
SJ Park, DW Park, YH Kim, SJ Kang, SW Lee, CW Lee… - New England Journal of Medicine, 2010